Oral GI Platform Leverage a unique protein therapeutic platform designed for oral delivery to the GI tract without systemic absorption. This approach creates opportunities for co development or licensing with metabolic disease programs seeking non invasive oral options.

Strategic Partnerships Position the company as a target for large pharma and specialty biotech seeking novel oral biologics, with a clear path to licensing the platform or engaging in co development to accelerate metabolic disease pipelines.

Cambridge Access Location in Cambridge, Massachusetts provides access to local biotech talent, academic collaborators, and contract research organizations to speed research, development, and manufacturing discussions.

VC Credibility Backed by top tier venture firms, the financing credibility supports outreach to potential partners and investors for joint ventures, milestone driven collaborations, or equity arrangements.

Lean Collaboration Lean and agile team enables scalable collaboration models where partners handle later stage development, regulatory, and manufacturing while the company focuses on platform advancement and early stage discovery.